This company has been marked as potentially delisted and may not be actively trading. NASDAQ:UBIO ProShares UltraPro Nasdaq Biotechnology (UBIO) Price, Holdings, & News Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About ProShares UltraPro Nasdaq Biotechnology (NASDAQ:UBIO) 30 days 90 days 365 days Advanced Chart Get UBIO alerts:Sign Up Key Stats Today's Range$17.61▼$17.6150-Day Range$17.61▼$17.7752-Week Range$13.13▼$35.36VolumeN/AAverage Volume42,922 shsMarket Capitalization$14.97 millionAssets Under Management$27.06 millionDividend Yield0.00%Net Expense Ratio0.95%Aggregate RatingN/A ETF OverviewRead More… ProShares UltraPro Nasdaq Biotechnology ExpensesTypeUBIOHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.75%0.57%0.57%0.54%0.53%Other Expenses0.57%0.30%0.48%0.42%0.51%Total Expense1.32%0.70%0.72%0.68%0.71%Fee Waiver-0.37%-0.45%-0.49%-0.29%-0.54%Net Expense0.95%0.61%0.63%0.62%0.60% Receive UBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProShares UltraPro Nasdaq Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address UBIO ETF News HeadlinesUltraShort Nasdaq Biotechnology declares quarterly distribution of $0.1326March 27, 2025 | msn.comMoleculin Biotech Stock (NASDAQ:MBRX) Dividends: History, Yield and DatesDecember 27, 2023 | benzinga.comBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%.June 6, 2025 | InvestorPlace (Ad)ProShares Trust - ProShares Ultra Nasdaq Cloud Computing (NASDAQ: SKYU)November 6, 2023 | fool.comProShares UltraPro Short Nasdaq BiotechnologyAugust 8, 2023 | thestreet.comPharmaCyte Biotech Stock (NASDAQ:PMCB), Quotes and News SummaryJanuary 5, 2023 | benzinga.comSee More Headlines UBIO ETF - Frequently Asked Questions What other stocks do shareholders of ProShares UltraPro Nasdaq Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that ProShares UltraPro Nasdaq Biotechnology investors own include Alibaba Group (BABA), Cresud Sociedad Anónima, Comercial, Inmobiliaria, Financiera y Agropecuaria (CRESW), Markel Group (MKL), NVIDIA (NVDA), Shopify (SHOP) and Energous (WATT). Fund Details IssuerProShares Fund NameProShares UltraPro NASDAQ Biotechnology Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:UBIO Inception Date6/22/2015 Fund ManagerMichael Neches, Tarak Dave WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkNASDAQ Biotechnology Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings0 Fund Statistics Assets Under Management$27.06 million Average Daily Volume$58.71 thousand Discount/Premium-0.04% Administrator, Advisor and Custodian AdministratorJ.P. Morgan Investor Services Co. AdvisorProShare Advisors LLC CustodianJPMorgan Chase Bank, N.A. DistributorSEI Investments Distribution Co. Transfer AgentJPMorgan Chase Bank, N.A. TrusteeN/A Lead Market MakerVirtu Financial Miscellaneous Outstanding Shares850,000BetaN/A The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report UBIO Sector ExposureUBIO Industry Exposure This page (NASDAQ:UBIO) was last updated on 6/6/2025 by MarketBeat.com Staff From Our PartnersElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredTrump’s Wealth Reset: Could You Be The First Beneficiary?Trump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major shift is coming this July — and Wall Street isn't waiting around. Thanks to a new rule going into e...American Alternative | SponsoredHow to target 627% gains from Trump’s tweetsPresident Trump is shaking up the market with his tweets and Truth Social posts... But while this chaos has...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProShares UltraPro Nasdaq Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Share ProShares UltraPro Nasdaq Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.